ArticleOncogene2014
A novel 3p22.3 gene CMTM7 represses oncogenic EGFR signaling and inhibits cancer cell growth.
Article in Oncogene, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 88 citations in OpenAlex.
- CMTM7 inhibits TLR4 signaling pathway via promoting Rab5 activation and alleviates acute liver injury.Cellular and molecular life sciences : CMLS · 2025Article
- CMTM4 is an adhesion modulator that regulates skeletal patterning and primary mesenchyme cell migration in sea urchin embryos.Developmental biology · 2025Article
- Immune-related gene SOX10 affects ferroptosis in pancreatic cancer and facilitates tumor progression by targeting CMTM7-mediated Wnt/β-catenin signaling pathway.European journal of medical research · 2025Article
- Comprehensive analysis of CMTM family and immune infiltration in esophageal carcinoma.PloS one · 2025Article
- The origin, evolution, and molecular diversity of the chemokine system.Life science alliance · 2024Article
- Review
- CMTM6: A Critical Prognostic Indicator in Non-Small Cell Lung Cancer.Journal of Cancer · 2024Article
- A New Saponin (Zygo-albuside D) fromACS omega · 2023Article
- CMTM7 inhibits breast cancer progression by regulating Wnt/β-catenin signaling.Breast cancer research : BCR · 2023Article
- [Advances in the Study of Chemokine-like Factor Superfamily Members in Tumors].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2023Review
- Clinicopathologic and prognostic significance of CMTM6 and PD-L1 expression in cervical squamous cell carcinoma.International journal of clinical and experimental pathology · 2023Article
- Comparative Assessment of the Antioxidant and Anticancer Activities ofAntioxidants (Basel, Switzerland) · 2022Article
- Inhibition of CMTM4 Sensitizes Cholangiocarcinoma and Hepatocellular Carcinoma to T Cell-Mediated Antitumor Immunity Through PD-L1.Hepatology communications · 2022Article
- CMTM6 and CMTM4 as two novel regulators of PD-L1 modulate the tumor microenvironment.Frontiers in immunology · 2022Review
- Expression and Clinical Significance ofBioMed research international · 2022Article
- StarGazer: A Hybrid Intelligence Platform for Drug Target Prioritization and Digital Drug Repositioning Using Streamlit.Frontiers in genetics · 2022Article
- CMTM Family and Gastrointestinal Tract Cancers: A Comprehensive Review.Cancer management and research · 2022Review
- CMTM Family Genes Affect Prognosis and Modulate Immunocytes Infiltration in Grade II/III Glioma Patients by Influencing the Tumor Immune Landscape and Activating Associated Immunosuppressing Pathways.Frontiers in cell and developmental biology · 2022Article
- Overexpressed CMTM6 Improves Prognosis and Associated With Immune Infiltrates of Ovarian Cancer.Frontiers in molecular biosciences · 2022Article
- CMTM5 inhibits the development of prostate cancer via the EGFR/PI3K/AKT signaling pathway.Molecular medicine reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Deletion of 3p12-22 is frequent in multiple cancer types, indicating the presence of critical tumor-suppressor genes (TSGs) at this region. We studied a novel candidate TSG, CMTM7, located at the 3p22.3 CMTM-gene cluster, for its tumor-suppressive functions and related mechanisms. The three CMTM genes, CMTM6, 7 and 8, are broadly expressed in human normal adult tissues and normal epithelial cell lines. Only CMTM7 is frequently silenced or downregulated in esophageal and nasopharyngeal cell lines, but uncommon in other carcinoma cell lines. Immunostaining of tissue microarrays for CMTM7 protein showed its downregulation or absence in esophageal, gastric, pancreatic, liver, lung and cervix tumor tissues. Promoter CpG methylation and loss of heterozygosity were both found contributing to CMTM7 downregulation. Ectopic expression of CMTM7 in carcinoma cells inhibits cell proliferation, motility and tumor formation in nude mice, but not in immortalized normal cells, suggesting a tumor inhibitory role of CMTM7. The tumor-suppressive function of CMTM7 is associated with its role in G1/S cell cycle arrest, through upregulating p27 and downregulating cyclin-dependent kinase 2 (CDK2) and 6 (CDK6). Moreover, CMTM7 could promote epidermal growth factor receptor (EGFR) internalization, and further suppress AKT signaling pathway. Thus, our findings suggest that CMTM7 is a novel 3p22 tumor suppressor regulating G1/S transition and EGFR/AKT signaling during tumor pathogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.